At 3.0% CAGR Acute Vulvovaginal Candidiasis Treatment Market To Reach US$ 397.8 Million By 2027, Finds Coherent Market Insights

SEATTLE, April 14, 2021, (PHARMIWEB) — Global Acute Vulvovaginal Candidiasis Market Analysis

Impact of the COVID-19 epidemic

The outbreak of COVID-19 virus is expected to hinder growth of the global acute vulvovaginal candidiasis market over the forecast period. In June 2020, as per the report from Indian Journal of Medical Sciences, the outbreak of coronavirus has influenced the conduction of clinical trials due to absence of staff, along with restricted travelling and product availability. These are the restraining factors in development of new treatments of acute vulvovaginal candidiasis.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/4315

Overview

The acute vulvovaginal candidiasis is a fungal infection which caused by a yeast known as Candida that usually resides in the body parts such as vagina, mouth, throat, and occasionally on skin. Generally, the Candida does not cause any problem until the environment of the vagina promotes the growth of this yeast, which will lead to its multiplication and infection. Factors causing this yeast infection are diabetes, high consumption of antibiotics, and aging. The most common symptoms of acute vulvovaginal candidiasis are vaginal soreness or itching, abnormal discharge, pain while urinating. Doctors recommend wearing cotton garments for the prevention of acute vulvovaginal candidiasis.

Drivers

Rising cases of acute vulvovaginal candidiasis across the globe is expected to boost growth of the global acute vulvovaginal candidiasis market during the forecast period. As per the article published in Lancet Journal in 2018, around 138 million women are suffering from acute vulvovaginal candidiasis globally, and the numbers are expected to reach 158 million by 2030.

Launch of newer products by various market players for treatment of the acute vulvovaginal candidiasis, is expected to propel the growth of global acute vulvovaginal candidiasis market during the forecast period. In July 2020, the Indian pharmaceuticals company Cadila Pharmaceuticals launched the Fenticonazole Nitrate Vaginal Capsules for treatment of acute vulvovaginal candidiasis.

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/acute-vulvovaginal-candidiasis-treatment-market-3576

Market Segmentation

By Distribution Channel: Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies.

By Route of Administration: Oral, Intravenous, and Topical.

By Drug Type: Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others.

Restraints

Rising concerns over the use of anti-fungal drugs and its side-effects is expected to restrain growth of the global acute vulvovaginal candidiasis market over the forecast period.

Regional Insights

North America is expected to witness a significant growth during the forecast period of global acute vulvovaginal candidiasis market. The provision of reimbursement policy for the testing and treatment of vaginal infections is driving the growth of acute vulvovaginal candidiasis market in this region.

Europe is expected to experience a robust growth over the forecast period of global acute vulvovaginal candidiasis market. Increasing cases of vaginal infections are driving the growth of acute vulvovaginal candidiasis market in this region. In 2019, the National Center for Biotechnology Information (NCBI) estimated that around 17% of total population of Sweden is suffering from fungal infections.

Key Players

Major players contributing in the global acute vulvovaginal candidiasis market are Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., Pfizer, Inc., Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., and Grupo Ferrer Internacional.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4315

Detailed Segmentation:

• Global Acute Vulvovaginal Candidiasis Treatment Market, By Drug Type:
  • Clotrimazole
  • Nystatin
  • Fluconazole
  • Ketoconazole
  • Terbinafine
  • Terconazole
  • Others
• Global Acute Vulvovaginal Candidiasis Treatment Market, By Route of Administration:
  • Oral
  • Intravenous
  • Topical
• Global Acute Vulvovaginal Candidiasis Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Acute Vulvovaginal Candidiasis Treatment Market, By Region:
  • North America
    • By Country
      • U.S.
      • Canada
    • By Drug Type:
      • Clotrimazole
      • Nystatin
      • Fluconazole
      • Ketoconazole
      • Terbinafine
      • Terconazole
      • Others
    • By Route of Administration
      • Oral
      • Intravenous
      • Topical
    • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837